FindTrial
Sign In

STUDY ON RELATIONSHIP OF BLOOD LEVELS OF COPEPTIN AND DISEASE OF OVARY

Serum Co-Peptin as a Biomarker of Polycystic ovarian syndrome and Its Correlation with Metabolic Syndrome components - -

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/09/045680
Enrollment
60
Registered
2022-09-19
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E282- Polycystic ovarian syndrome

Interventions

Intervention1: NA: NA

Sponsors

FATHER MULLER MEDICAL COLLEGE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients fulfilling all the features of Rotterdamââ?¬•s criteria diagnosed as PCOS.

Exclusion criteria

Exclusion criteria: Based on history and clinical records � H/O smoking � Diabetes mellitus � Hyperprolactinemia � Congenital adrenal hyperplasia � Androgen-secreting tumors � Thyroid disorders � Cushing syndrome (1 mg dexamethasone suppression test) � Infectious diseases � Hypertension � Hepatic or renal dysfunction. � Usage within 3 months before enrollment confounding medications, including oral contraceptive agents, antilipidemic drugs, hypertensive medications, and insulin-sensitizing drugs

Design outcomes

Primary

MeasureTime frame
1. sensitivity and specificity of copeptin as biomarker of PCOS, will be analyzed. Further relationship of copeptin levels to those having metabolic syndrome in PCOS will also be studiedTimepoint: BASELINE VALUE AT RECRUITMENT OF PARTICIPANTS—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactPREMA DCUNHA

FATHER MULLER MEDICAL COLLEGE

prema_dcunha@fathermuller.in09845342488

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026